SG11201806134SA - Oncolytic viral vectors and uses thereof - Google Patents
Oncolytic viral vectors and uses thereofInfo
- Publication number
- SG11201806134SA SG11201806134SA SG11201806134SA SG11201806134SA SG11201806134SA SG 11201806134S A SG11201806134S A SG 11201806134SA SG 11201806134S A SG11201806134S A SG 11201806134SA SG 11201806134S A SG11201806134S A SG 11201806134SA SG 11201806134S A SG11201806134S A SG 11201806134SA
- Authority
- SG
- Singapore
- Prior art keywords
- oncr
- international
- mir
- rule
- viral vectors
- Prior art date
Links
- 239000013603 viral vector Substances 0.000 title abstract 4
- 230000000174 oncolytic effect Effects 0.000 title abstract 3
- 108700011259 MicroRNAs Proteins 0.000 abstract 5
- 239000002679 microRNA Substances 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 108091056924 miR-124 stem-loop Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 101150027427 ICP4 gene Proteins 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 210000005265 lung cell Anatomy 0.000 abstract 1
- 101710130522 mRNA export factor Proteins 0.000 abstract 1
- 108091084079 miR-12 stem-loop Proteins 0.000 abstract 1
- 108091044988 miR-125a stem-loop Proteins 0.000 abstract 1
- 108091049513 miR-125a-1 stem-loop Proteins 0.000 abstract 1
- 108091040046 miR-125a-2 stem-loop Proteins 0.000 abstract 1
- 230000000394 mitotic effect Effects 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000002100 tumorsuppressive effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
4 U 3000 Mock ONCR-003 ONCR-011 2000 0 0. LI 1000 u- 0 ▪ Mock • ONCR-003 ONCR-011 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/132552 Al 3 August 2017 (03.08.2017) WIPO I PCT (51) International Patent Classification: C12N 7/00 (2006.01) (21) International Application Number: PCT/US2017/015417 (22) International Filing Date: 27 January 2017 (27.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/287,619 27 January 2016 (27.01.2016) US (71) Applicant: ONCORUS, INC. [US/US]; 450 Kendall Street, 4th Floor, Cambridge, Massachusetts 02142 (US). (72) Inventors: GREENBERG, Kenneth P.; c/o Oncorus, Inc., 450 Kendall Street, 4th Floor, Cambridge, Massachu- setts 02142 (US). FINER, Mitchell H.; c/o Oncorus, Inc., 450 Kendall Street, 4th Floor, Cambridge, Massachusetts 02142 (US). (74) Agents: PHELAN, Jordan D. et al.; Cooley LLP, 1299 Pennsylvania Avenue, N.W., Suite 700, Washington, Dis- trict of Columbia 20004-2400 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ONCOLYTIC VIRAL VECTORS AND USES THEREOF FIG. 33 11111111111111 0 111011111111111 010 11111 01110111 0111 OIEH11111 0111111111 0111111 Vector ICP4 miRNA site ICP27 miRNA site ONCR-003 miR-124 None ONCR-011 miR-124 miR-12 5 Post - mitotic Lung Cells miR 125a miR 124 PM-Lung >3000 <100 H 8, N CA <100 <100 A253 H & N Cancer cells W O 20 17 / 13 255 2 Al 600 2 TD 400 0 0 - 200 0. LL 0 17.‘ 1±\ b' 0 0 0 (57) : The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. 4 1 %
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662287619P | 2016-01-27 | 2016-01-27 | |
PCT/US2017/015417 WO2017132552A1 (en) | 2016-01-27 | 2017-01-27 | Oncolytic viral vectors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806134SA true SG11201806134SA (en) | 2018-08-30 |
Family
ID=57995301
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806134SA SG11201806134SA (en) | 2016-01-27 | 2017-01-27 | Oncolytic viral vectors and uses thereof |
SG10202107138TA SG10202107138TA (en) | 2016-01-27 | 2017-01-27 | Oncolytic viral vectors and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202107138TA SG10202107138TA (en) | 2016-01-27 | 2017-01-27 | Oncolytic viral vectors and uses thereof |
Country Status (18)
Country | Link |
---|---|
US (3) | US10391132B2 (en) |
EP (2) | EP4089166A1 (en) |
JP (4) | JP2019508063A (en) |
KR (1) | KR20180136435A (en) |
CN (2) | CN108884448B (en) |
AR (1) | AR107469A1 (en) |
AU (1) | AU2017212713B2 (en) |
BR (1) | BR112018015390A2 (en) |
CA (1) | CA3011933A1 (en) |
DK (1) | DK3408382T3 (en) |
ES (1) | ES2919953T3 (en) |
IL (2) | IL260790B (en) |
MX (1) | MX2018009126A (en) |
PT (1) | PT3408382T (en) |
RU (2) | RU2749050C2 (en) |
SG (2) | SG11201806134SA (en) |
TW (1) | TWI798168B (en) |
WO (1) | WO2017132552A1 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4089166A1 (en) | 2016-01-27 | 2022-11-16 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
SG11201811600PA (en) | 2016-06-30 | 2019-01-30 | Oncorus Inc | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
US10682425B2 (en) | 2016-12-14 | 2020-06-16 | The Regents Of The University Of California | Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them |
CN110520526B (en) * | 2017-04-19 | 2023-06-09 | 国立大学法人东京大学 | Genetically engineered coxsackieviruses and pharmaceutical compositions |
US10975444B2 (en) * | 2017-04-28 | 2021-04-13 | Toray Industries, Inc. | Kit, device, and method for detecting ovarian tumor |
RU2771110C2 (en) * | 2017-07-26 | 2022-04-26 | Онкорус, Инк. | Oncolytic viral vectors and their application |
GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
CN111065732A (en) | 2017-09-11 | 2020-04-24 | Imba-莫利库尔生物技术研究所 | Tumor organoid model |
TWI666321B (en) * | 2017-10-23 | 2019-07-21 | 大陸商深圳市亦諾微醫藥科技有限公司 | Construction of oncolytic herpes simplex viruses (ohsv) obligate vector and constructs for cancer therapy |
CN107723367A (en) * | 2017-10-27 | 2018-02-23 | 青岛大学 | Application of miRNA-885-3p and product using same |
CN107674918A (en) * | 2017-11-10 | 2018-02-09 | 上海交通大学医学院 | Applications of the 5p of has mir 195 as biomarker in pulmonary cancer diagnosis kit is prepared |
WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
EP4008333A1 (en) | 2018-02-19 | 2022-06-08 | Combined Therapeutics, Inc. | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
CA3096938A1 (en) * | 2018-04-10 | 2019-10-17 | Ottawa Hospital Research Institute | Microrna-based compositions and methods used in disease treatment |
EP3781188A4 (en) * | 2018-04-13 | 2022-03-02 | 2seventy bio, Inc. | Adoptive cellular therapy |
CN108707625B (en) * | 2018-07-03 | 2021-09-21 | 云笛生物科技有限公司 | mir-124 and HER2-shRNA double-gene expression cassette virus vector, construction method, virus and application |
CN109091492A (en) * | 2018-08-02 | 2018-12-28 | 广州安镝声生物医药科技有限公司 | The target miRNA miR-106b-5p of lncRNA H19 and its application |
CN109091491A (en) * | 2018-08-02 | 2018-12-28 | 广州安镝声生物医药科技有限公司 | The target miRNA miR19a-3p of lncRNA H19 and its application |
CN111117973A (en) * | 2018-10-30 | 2020-05-08 | 中国科学院武汉病毒研究所 | Recombinant oncolytic enterovirus 71 regulated and controlled by microRNA and application thereof |
SG11202104887UA (en) * | 2018-11-13 | 2021-06-29 | Oncorus Inc | Encapsulated polynucleotides and methods of use |
TWI690597B (en) * | 2018-11-14 | 2020-04-11 | 國立中央大學 | Detection kit and detection method for urothelial carcinoma |
AU2019389108A1 (en) * | 2018-11-29 | 2021-06-17 | Virogin Biotech Canada Ltd | HSV vector with reduced neurotoxicity |
WO2020117003A1 (en) * | 2018-12-06 | 2020-06-11 | 국립암센터 | Composition comprising nc886 for improving oncolytic virus activity or production |
AU2020204989A1 (en) * | 2019-01-04 | 2021-07-08 | Elevatebio Technologies, Inc. | Encapsulated RNA polynucleotides and methods of use |
CN109762903B (en) * | 2019-01-31 | 2022-02-01 | 山东大学齐鲁医院 | Application of miR-1246 and/or TERF2IP in diagnosis and treatment of glioma |
EP3938524A1 (en) * | 2019-03-14 | 2022-01-19 | Massachusetts Institute of Technology | Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof |
CN110283794B (en) * | 2019-05-30 | 2021-04-23 | 伍泽堂 | Recombinant oncolytic virus, preparation method, application and medicament thereof |
CN112011570B (en) * | 2019-05-31 | 2023-04-18 | 北京合生基因科技有限公司 | Oncolytic virus system for specifically killing tumor cells and application thereof |
US20220356529A1 (en) * | 2019-07-16 | 2022-11-10 | Université Cote D'azur | Method of assessing the sensitivity or resistance of a subject to an oncolytic virus, recombinant virus, preparation and uses thereof |
CA3150053A1 (en) * | 2019-08-05 | 2021-02-11 | Virogin Biotech Canada Ltd | Genetically modified enterovirus vectors |
CN110468132B (en) * | 2019-08-15 | 2022-11-25 | 西南大学 | sgRNA, transgenic expression vector, expression strain and screening method |
CN110433171B (en) * | 2019-08-20 | 2022-08-19 | 中山大学附属第六医院 | Application of miRNA-1293 in preparation of anti-colorectal tumor medicine |
EP4041902A1 (en) | 2019-10-10 | 2022-08-17 | Oncorus, Inc. | Dual viruses and dual oncolytic viruses and methods of treatment |
KR102320430B1 (en) * | 2020-01-29 | 2021-11-03 | 서울대학교병원 | Use of miR-135b, miR-135a and their target gene AMOTL2 for medulloblastoma |
EP4136241A2 (en) * | 2020-04-14 | 2023-02-22 | Eidgenössische Technische Hochschule Zürich | Cell classifier circuits and methods of use thereof |
CN113583977A (en) * | 2020-04-30 | 2021-11-02 | 杭州康万达医药科技有限公司 | Isolated recombinant oncolytic poxvirus regulated by microRNA and application thereof |
WO2021244628A1 (en) * | 2020-06-05 | 2021-12-09 | 上海宝济药业有限公司 | Pharmaceutical composition of enzymes and viruses and application thereof |
AU2021326420A1 (en) | 2020-07-31 | 2023-03-09 | Combined Therapeutics, Inc. | Compositions and methods for improved vaccination |
EP4243849A1 (en) * | 2020-11-13 | 2023-09-20 | Technische Universität Berlin | Mir-375- and mir-1-regulated coxsackievirus b3 has no pancreas and heart toxicity but strong antitumor efficiency in colorectal carcinomas |
WO2022133970A1 (en) * | 2020-12-25 | 2022-06-30 | 苏州系统医学研究所 | Composition comprising oncolytic virus and application thereof in tumor treatment |
WO2023034867A1 (en) * | 2021-08-31 | 2023-03-09 | Oncorus, Inc. | Engineered oncolytic herpesviruses |
CN113637761A (en) * | 2021-10-15 | 2021-11-12 | 北京百奥思科生物医学技术有限公司 | MiRNA marker for diagnosing and treating melanoma and related product thereof |
WO2023142040A1 (en) * | 2022-01-29 | 2023-08-03 | Virogin Biotech Canada Ltd. | Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors |
CN115381849A (en) * | 2022-06-27 | 2022-11-25 | 浙江大学 | Active component of anti-oral tumor medicine and application thereof |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5244792A (en) | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
JPH0668B2 (en) | 1985-08-30 | 1994-01-05 | 財団法人化学及血清療法研究所 | Recombinant plasmid with herpes simplex virus gene |
GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
US5849571A (en) | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
DE69312487T2 (en) | 1992-05-18 | 1997-11-27 | Minnesota Mining & Mfg | DEVICE FOR TRANSMUCOSAL DELIVERY OF ACTIVE SUBSTANCES |
US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US5879934A (en) | 1992-07-31 | 1999-03-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
GB9415369D0 (en) | 1994-07-29 | 1994-09-21 | Lynxvale Ltd | Mutant virus |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US6261552B1 (en) | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
GB9700411D0 (en) | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
US6071742A (en) | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
EP1037991B1 (en) | 1997-12-17 | 2005-09-28 | Immunex Corporation | Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides |
EP1002864A1 (en) | 1998-11-10 | 2000-05-24 | Universita' degli studi di Bologna | HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections |
US6897057B1 (en) | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
GB9930418D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
WO2002076216A1 (en) | 2001-03-27 | 2002-10-03 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
WO2002088327A1 (en) | 2001-04-06 | 2002-11-07 | Mount Sinai School Of Medicine Of New York University | Methods for viral oncoapoptosis in cancer therapy |
MXPA04003057A (en) | 2001-10-04 | 2005-06-20 | Immunex Corp | Ul16 binding protein 4. |
KR100900249B1 (en) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | SIVmac239 Immunogenic Plasmids And AIDS DNA Vaccine Containing The Same |
US8927251B2 (en) | 2002-10-07 | 2015-01-06 | The University Of Chicago | Targeting of herpes simplex virus to specific receptors |
GB0406389D0 (en) | 2004-03-22 | 2004-04-21 | Istituto Superiore Di Sanito | Recombinant herpes simplex virus and uses therefor |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
KR101295733B1 (en) | 2004-08-20 | 2013-08-13 | 비랄리틱스 리미티드 | Methods and compositions for treatment of hematologic cancers |
WO2006050211A2 (en) | 2004-10-28 | 2006-05-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
WO2006074526A1 (en) | 2005-01-17 | 2006-07-20 | Viralytics Limited | Method and composition for treatment of neoplasms |
KR20130114758A (en) | 2005-05-27 | 2013-10-17 | 오스페달레 산 라파엘 에스.알.엘. | Gene vector comprising mi-rna |
EP2325332B1 (en) | 2005-08-26 | 2012-10-31 | DuPont Nutrition Biosciences ApS | Use of CRISPR associated genes (CAS) |
US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
US20080008686A1 (en) | 2006-07-10 | 2008-01-10 | The Brigham And Women's Hospital, Inc. | Tetracycline repressor regulated oncolytic viruses |
CA2660485C (en) | 2006-08-11 | 2016-04-12 | Sangamo Biosciences, Inc. | Zinc finger nuclease-mediated homologous recombination |
EP2125032A4 (en) | 2007-02-20 | 2011-02-23 | Mayo Foundation | Treating cancer with viral nucleic acid |
EP2144632B1 (en) | 2007-05-09 | 2016-11-16 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Synthetic herpes simplex viruses type-1 for treatment of cancers |
US20080289058A1 (en) | 2007-05-14 | 2008-11-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
WO2009111892A1 (en) | 2008-03-14 | 2009-09-17 | Ottawa Health Research Institute | Microrna mediated oncolytic targeting |
US8703120B2 (en) | 2008-05-29 | 2014-04-22 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
PL2293804T3 (en) | 2008-05-29 | 2014-03-31 | Univ Bologna Alma Mater Studiorum | Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof |
GB0810912D0 (en) | 2008-06-13 | 2008-07-23 | Inst Animal Health Ltd | Vector |
WO2010011961A2 (en) | 2008-07-25 | 2010-01-28 | University Of Georgia Research Foundation, Inc. | Prokaryotic rnai-like system and methods of use |
US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
WO2010054108A2 (en) | 2008-11-06 | 2010-05-14 | University Of Georgia Research Foundation, Inc. | Cas6 polypeptides and methods of use |
RU2570562C2 (en) | 2008-11-07 | 2015-12-10 | ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС | Bifidobacteria crispr sequences |
WO2010105277A1 (en) | 2009-03-13 | 2010-09-16 | Egen, Inc. | Compositions and methods for the delivery of biologically active rnas |
US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
US20130071430A1 (en) | 2010-04-09 | 2013-03-21 | The University Of Tokyo | Microrna-controlled recombinant vaccinia virus and use thereof |
US9593347B2 (en) | 2010-04-16 | 2017-03-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors |
WO2012006181A2 (en) | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
NZ607870A (en) | 2010-10-20 | 2015-09-25 | Dupont Nutrition Biosci Aps | Lactococcus crispr-cas sequences |
BR112013025567B1 (en) | 2011-04-27 | 2021-09-21 | Amyris, Inc | METHODS FOR GENOMIC MODIFICATION |
US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
EP2591796A1 (en) | 2011-11-10 | 2013-05-15 | Universität Zürich | Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy |
PL3351261T3 (en) | 2011-10-11 | 2021-12-06 | Universität Zürich | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
US20140363469A1 (en) * | 2012-01-19 | 2014-12-11 | Alnylam Pharmaceuticals, Inc. | Viral attenuation and vaccine production |
DK2836226T3 (en) | 2012-02-24 | 2017-09-18 | Hutchinson Fred Cancer Res | COMPOSITIONS AND PROCEDURES FOR TREATING HEMOGLOBINOPATHY |
WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
CN112162094A (en) | 2013-01-04 | 2021-01-01 | 西托姆克斯治疗公司 | Compositions and methods for detecting protease activity in biological systems |
JP6702858B2 (en) | 2013-06-17 | 2020-06-03 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, use and therapeutic applications of CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
CN105637092B (en) | 2013-07-17 | 2021-06-11 | 匹兹堡大学-属高等教育联邦体系 | Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production |
ES2781852T3 (en) * | 2013-10-28 | 2020-09-08 | Univ Pittsburgh Commonwealth Sys Higher Education | Oncolytic HSV vector |
JP6857498B2 (en) | 2014-02-27 | 2021-04-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Combination method for treating cancer |
CA3190510A1 (en) | 2014-07-16 | 2016-01-21 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
EP4226937A3 (en) | 2015-03-05 | 2023-09-27 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
US10083137B2 (en) | 2015-04-02 | 2018-09-25 | Atmel Corporation | Peripheral interface circuit for serial memory |
US20180318365A1 (en) | 2015-10-19 | 2018-11-08 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
ES2831080T5 (en) | 2016-01-08 | 2023-10-30 | Replimune Ltd | Modified oncolytic virus |
EP4089166A1 (en) | 2016-01-27 | 2022-11-16 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
JP7208492B2 (en) | 2016-03-10 | 2023-01-19 | シージー オンコロジー, インコーポレイテッド | Methods of treating solid tumors or lymphoid tumors with combination therapy |
EP3380621A4 (en) | 2016-04-22 | 2019-05-08 | Immvira Co., Limited | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
JP7200104B2 (en) | 2016-08-01 | 2023-01-06 | ヴァイロジン バイオテック カナダ リミテッド | Oncolytic Herpes Simplex Virus Vectors Expressing Immune System Stimulatory Molecules |
EP3497208A4 (en) | 2016-08-09 | 2020-03-11 | Turnstone Limited Partnership | Oncolytic rhabdovirus expressing il12 |
TW201825674A (en) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | Oncolytic virus expressing bispecific engager molecules |
WO2018085461A1 (en) | 2016-11-01 | 2018-05-11 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
WO2018118967A1 (en) | 2016-12-21 | 2018-06-28 | Memgen, Llc | Armed replication-competent oncolytic adenoviruses |
US11298420B2 (en) | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
RU2771110C2 (en) | 2017-07-26 | 2022-04-26 | Онкорус, Инк. | Oncolytic viral vectors and their application |
-
2017
- 2017-01-27 EP EP22161034.8A patent/EP4089166A1/en active Pending
- 2017-01-27 SG SG11201806134SA patent/SG11201806134SA/en unknown
- 2017-01-27 JP JP2018559162A patent/JP2019508063A/en active Pending
- 2017-01-27 AU AU2017212713A patent/AU2017212713B2/en not_active Expired - Fee Related
- 2017-01-27 AR ARP170100218A patent/AR107469A1/en unknown
- 2017-01-27 CN CN201780019076.0A patent/CN108884448B/en active Active
- 2017-01-27 RU RU2018130673A patent/RU2749050C2/en active
- 2017-01-27 DK DK17704150.6T patent/DK3408382T3/en active
- 2017-01-27 EP EP17704150.6A patent/EP3408382B1/en active Active
- 2017-01-27 MX MX2018009126A patent/MX2018009126A/en unknown
- 2017-01-27 ES ES17704150T patent/ES2919953T3/en active Active
- 2017-01-27 CA CA3011933A patent/CA3011933A1/en active Pending
- 2017-01-27 BR BR112018015390-7A patent/BR112018015390A2/en active Search and Examination
- 2017-01-27 KR KR1020187024583A patent/KR20180136435A/en active Search and Examination
- 2017-01-27 SG SG10202107138TA patent/SG10202107138TA/en unknown
- 2017-01-27 CN CN202211588793.4A patent/CN116904404A/en active Pending
- 2017-01-27 PT PT177041506T patent/PT3408382T/en unknown
- 2017-01-27 WO PCT/US2017/015417 patent/WO2017132552A1/en active Application Filing
- 2017-01-27 RU RU2021114137A patent/RU2021114137A/en unknown
- 2017-02-02 TW TW106103584A patent/TWI798168B/en active
-
2018
- 2018-07-26 IL IL260790A patent/IL260790B/en unknown
- 2018-07-27 US US16/047,499 patent/US10391132B2/en active Active
-
2019
- 2019-07-10 US US16/507,789 patent/US11452750B2/en active Active
-
2021
- 2021-05-27 JP JP2021089151A patent/JP7174109B2/en active Active
-
2022
- 2022-01-25 IL IL290102A patent/IL290102B2/en unknown
- 2022-08-18 US US17/820,694 patent/US20230115116A1/en active Pending
- 2022-11-04 JP JP2022177413A patent/JP2023001236A/en not_active Withdrawn
-
2024
- 2024-02-28 JP JP2024028567A patent/JP2024052881A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806134SA (en) | Oncolytic viral vectors and uses thereof | |
SG11201901841TA (en) | Targeting ligands | |
SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
SG11201900910TA (en) | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | |
SG11201903282TA (en) | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201900447SA (en) | Methods and compositions for modifying genomic dna | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201809522WA (en) | Method of nucleic acid sequence determination | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201806419RA (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201811600PA (en) | Pseudotyped oncolytic viral delivery of therapeutic polypeptides | |
SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
SG11201810179RA (en) | Novel crispr enzymes and systems | |
SG11201807187XA (en) | Binding members to pd-l1 | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
SG11201804934PA (en) | Novel Compounds | |
SG11201811408PA (en) | Adoptive cell transfer and oncolytic virus combination therapy | |
SG11201807134RA (en) | Transposon system and methods of use | |
SG11201808176TA (en) | Gene therapy for treating mucopolysaccharidosis type ii |